Patents by Inventor Toshiyuki Morichika
Toshiyuki Morichika has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230340134Abstract: The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.Type: ApplicationFiled: June 15, 2023Publication date: October 26, 2023Inventors: Toshiyuki MORICHIKA, Daisuke KAMEOKA, Yoshimi IMAEDA, Terutoshi MAEDA, Oliver Boris STAUCH
-
Patent number: 11767363Abstract: The problem to be solved is to provide a humanized anti-IL-6 receptor antibody AMA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.Type: GrantFiled: January 31, 2023Date of Patent: September 26, 2023Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, HOFFMANN-LA ROCHE INC.Inventors: Toshiyuki Morichika, Daisuke Kameoka, Yoshimi Imaeda, Terutoshi Maeda, Oliver Boris Stauch
-
Publication number: 20230167183Abstract: The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.Type: ApplicationFiled: January 31, 2023Publication date: June 1, 2023Inventors: Toshiyuki MORICHIKA, Daisuke KAMEOKA, Yoshimi IMAEDA, Terutoshi MAEDA, Oliver Boris STAUCH
-
Patent number: 11584798Abstract: The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.Type: GrantFiled: May 25, 2022Date of Patent: February 21, 2023Assignees: HOFFMANN-LA ROCHE INC., CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Toshiyuki Morichika, Daisuke Kameoka, Yoshimi Imaeda, Terutoshi Maeda, Oliver Boris Stauch
-
Publication number: 20220281988Abstract: The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.Type: ApplicationFiled: May 25, 2022Publication date: September 8, 2022Inventors: Toshiyuki MORICHIKA, Daisuke KAMEOKA, Yoshimi IMAEDA, Terutoshi MAEDA, Oliver Boris STAUCH
-
Patent number: 11359026Abstract: The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.Type: GrantFiled: April 27, 2021Date of Patent: June 14, 2022Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, HOFFMANN-LA ROCHE INC.Inventors: Toshiyuki Morichika, Daisuke Kameoka, Yoshimi Imaeda, Terutoshi Maeda, Oliver Boris Stauch
-
Publication number: 20210246216Abstract: The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.Type: ApplicationFiled: April 27, 2021Publication date: August 12, 2021Inventors: Toshiyuki MORICHIKA, Daisuke KAMEOKA, Yoshimi IMAEDA, Terutoshi MAEDA, Oliver Boris STAUCH
-
Patent number: 11008394Abstract: The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.Type: GrantFiled: April 22, 2019Date of Patent: May 18, 2021Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, F. HOFFMANN-LA ROCHE AGInventors: Toshiyuki Morichika, Daisuke Kameoka, Yoshimi Imaeda, Terutoshi Maeda, Oliver Boris Stauch
-
Publication number: 20200079857Abstract: The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.Type: ApplicationFiled: April 22, 2019Publication date: March 12, 2020Inventors: Toshiyuki MORICHIKA, Daisuke KAMEOKA, Yoshimi IMAEDA, Terutoshi MAEDA, Oliver Boris STAUCH
-
Patent number: 10316096Abstract: The present invention relates to antibody-containing lyophilized formulations free from reducing sugars, non-reducing sugars, sugar alcohols or polysaccharides as excipients and including one or more amino acid selected from the group consisting of arginine, histidine, lysine, serine, proline, glycine, alanine and threonine or a salt thereof.Type: GrantFiled: June 23, 2015Date of Patent: June 11, 2019Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Toshiyuki Morichika, Daisuke Kameoka
-
Publication number: 20160090419Abstract: The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.Type: ApplicationFiled: December 9, 2015Publication date: March 31, 2016Inventors: Toshiyuki MORICHIKA, Daisuke KAMEOKA, Yoshimi IMAEDA, Terutoshi MAEDA, Oliver Boris STAUCH
-
Publication number: 20150284466Abstract: The present invention relates to antibody-containing lyophilized formulations free from reducing sugars, non-reducing sugars, sugar alcohols or polysaccharides as excipients and including one or more amino acid selected from the group consisting of arginine, histidine, lysine, serine, proline, glycine, alanine and threonine or a salt thereof.Type: ApplicationFiled: June 23, 2015Publication date: October 8, 2015Inventors: Toshiyuki MORICHIKA, Daisuke KAMEOKA
-
Patent number: 9084777Abstract: The present invention relates to antibody-containing lyophilized formulations free from reducing sugars, non-reducing sugars, sugar alcohols or polysaccharides as excipients and including one or more amino acid selected from the group consisting of arginine, histidine, lysine, serine, proline, glycine, alanine and threonine or a salt thereof.Type: GrantFiled: December 27, 2006Date of Patent: July 21, 2015Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Toshiyuki Morichika, Daisuke Kameoka
-
Publication number: 20140005367Abstract: The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.Type: ApplicationFiled: September 3, 2013Publication date: January 2, 2014Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Toshiyuki MORICHIKA, Daisuke Kameoka, Yoshimi Imaeda, Terutoshi Maeda, Oliver Boris Stauch
-
Patent number: 8568720Abstract: The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.Type: GrantFiled: December 26, 2008Date of Patent: October 29, 2013Assignees: Chugai Seiyaku Kabushiki Kaisha, F. Hoffmann - La Roche AGInventors: Toshiyuki Morichika, Daisuke Kameoka, Yoshimi Imaeda, Terutoshi Maeda, Oliver Boris Stauch
-
Publication number: 20100285011Abstract: The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.Type: ApplicationFiled: December 26, 2008Publication date: November 11, 2010Applicants: Chugai Seiyaku Kabushiki Kaish, F.Hoffman - La Roche AGInventors: Toshiyuki Morichika, Daisuke Kameoka, Yoshimi Imaeda, Terutoshi Maeda, Oliver Boris Stauch
-
Publication number: 20090291076Abstract: The present invention relates to antibody-containing lyophilized formulations free from reducing sugars, non-reducing sugars, sugar alcohols or polysaccharides as excipients and including one or more amino acid selected from the group consisting of arginine, histidine, lysine, serine, proline, glycine, alanine and threonine or a salt thereof.Type: ApplicationFiled: December 27, 2006Publication date: November 26, 2009Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Toshiyuki Morichika, Daisuke Kameoka
